OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

Optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) leads to a larger minimum stent area but does not reduce the two-year rate of target vessel failure compared with angiography-guided PCI, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

Abecma sales disappoint again as BCMA competition ramps up, FDA adcomm looms

Fourth-quarter US sales of Bristol Myers Squibb’s BCMA-targeting CAR-T therapy Abecma last year declined by 40% compared to the same period in 2022, primarily due

February 3, 2024

DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA – Biotech Investments

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS

July 9, 2024

New vaccine against Strep A could drastically cut antibiotic use for sore throats, study suggests

Study predicts that a vaccine against group A Streptococcus (Strep A) could significantly reduce antibiotic prescriptions for sore throat, potentially leading to a 33% decrease

November 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.